

## **RAW SEQUENCE LISTING**

**The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) no errors detected.**

Application Serial Number: 10/675,470A  
Source: 1FW16  
Date Processed by STIC: 4/29/05

# ***ENTERED***



IFW16

## RAW SEQUENCE LISTING

DATE: 04/29/2005

PATENT APPLICATION: US/10/675,470A

TIME: 12:06:59

Input Set : E:\SEQUENCE LISTING-revised 2.txt

Output Set: N:\CRF4\04292005\J675470A.raw

## SEQUENCE LISTING

```

3 (1) GENERAL INFORMATION:
5   (i) APPLICANT: Joseph W Harding and John W Wright
6   (ii) TITLE OF INVENTION: AT4 Ligands as Anti-Angiogenic and Anti-Tumor Agents
7   (iii) NUMBER OF SEQUENCES: 5
8   (iv) CORRESPONDENCE ADDRESS:
9       (A) ADDRESSEE: Pacific Northwest Biotechnology, Inc.
10      (B) STREET: SE 745 Derby Street
11      (C) CITY: Pullman
12      (D) STATE: Washington
13      (E) COUNTRY: United States of America
14      (F) ZIP: 99163
15   (v) COMPUTER READABLE FORM:
16       (A) MEDIUM TYPE: CD, 700MB
17       (B) COMPUTER: PC
18       (C) OPERATING SYSTEM: WINDOWS XP
19       (D) SOFTWARE: OFFICE WORD
20   (vi) CURRENT APPLICATION DATA:
C--> 21       (A) APPLICATION NUMBER: US/10/675,470A
C--> 22       (B) FILING DATE: 30-Sep-2003
23       (C) CLASSIFICATION: 530/300
24   (viii) ATTORNEY/AGENT INFORMATION:
25       (A) NAME: John Hughs
26       (B) REGISTRATION NUMBER: 47,236
27   (ix) TELECOMMUNICATION INFORMATION:
28       (A) TELEPHONE: (509) 335-7927; (509) 332-3178
29       (B) TELEFAX: (509) 335-4650
31 (2) INFORMATION FOR SEQ ID NO: 1:
32   (i) SEQUENCE CHARACTERISTICS:
33       (A) LENGTH: 4 amino acids
34       (B) TYPE: amino acid
35       (D) TOPOLOGY: linear
36   (ii) MOLECULE TYPE: peptide
37   (v) FRAGMENT TYPE: N-terminal
38   (ix) FEATURE:
39       (D) OTHER INFORMATION: Xaa is norleucine
40   (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:
W--> 41       Xaa Tyr Ile His
43 (2) INFORMATION FOR SEQ ID NO: 2:
44   (i) SEQUENCE CHARACTERISTICS:
45       (A) LENGTH: 4 amino acids
46       (B) TYPE: amino acid
47       (D) TOPOLOGY: linear

```

## RAW SEQUENCE LISTING

DATE: 04/29/2005

PATENT APPLICATION: US/10/675,470A

TIME: 12:06:59

Input Set : E:\SEQUENCE LISTING-revised 2.txt

Output Set: N:\CRF4\04292005\J675470A.raw

```

48      (ii) MOLECULE TYPE: peptide
49      (v) FRAGMENT TYPE: N-terminal
50      (ix) FEATURE:
51          (D) OTHER INFORMATION: Xaa(1)is norleucine; Xaa(4) is 6-aminohexanoic
52 acid; amidation
53      (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:
W--> 54      Xaa Tyr Ile Xaa
56 (2) INFORMATION FOR SEQ ID NO: 3:
57      (i) SEQUENCE CHARACTERISTICS:
58          (A) LENGTH: 6 amino acids
59          (B) TYPE: amino acid
60          (D) TOPOLOGY: linear
61      (ii) MOLECULE TYPE: peptide
62      (v) FRAGMENT TYPE: N-terminal
63      (ix) FEATURE:
64          (D) OTHER INFORMATION: Xaa(1) is Norleucine
65      (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:
W--> 66      Xaa Tyr Ile His Pro Phe
67          5
69 (2) INFORMATION FOR SEQ ID NO: 4:
70      (i) SEQUENCE CHARACTERISTICS:
71          (A) LENGTH: 6 amino acids
72          (B) TYPE: amino acid
73          (D) TOPOLOGY: linear
74      (ii) MOLECULE TYPE: peptide
75      (v) FRAGMENT TYPE: N-terminal
76      (ix) FEATURE:
77          (D) OTHER INFORMATION: Xaa is norleucine; Leu(3)-His(4) has a methylene bond
78      (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:
W--> 79      Xaa Tyr Leu His Pro Phe
80          5
82 (2) INFORMATION FOR SEQ ID NO: 5:
83      (i) SEQUENCE CHARACTERISTICS:
84          (A) LENGTH: 6 amino acids
85          (B) TYPE: amino acid
86          (D) TOPOLOGY: linear
87      (ii) MOLECULE TYPE: peptide
88      (v) FRAGMENT TYPE: N-terminal
89      (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:
90          Val Tyr Ile His Pro Phe
91          5

```